Use of progesterone supplement therapy for prevention of preterm birth: review of literatures

키워드

참고문헌 (86)

1. Blencowe H, "National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries:a systematic analysis and implications", Lancet, 379, pp.2162~2172 (2012)
2. "Birth statistics" (2016)[URL]
3. Natarajan G, "Short- and long-term outcomes of moderate and late preterm infants", Am J Perinatol, 33, pp.305~317 (2016)
4. Harrison MS, "Global burden of prematurity", Semin Fetal Neonatal Med, 21, pp.74~79 (2016)
5. Khan KS, "Risk screening for spontaneous preterm labour", Best Pract Res Clin Obstet Gynaecol, 21, pp.821~830 (2007)
6. Newnham JP, "Strategies to prevent preterm birth", Front Immunol, 5, pp.584~ (2014)
7. da Fonseca EB, "Prematurity prevention: the role of progesterone", Curr Opin Obstet Gynecol, 21, pp.142~147 (2009)
8. Romero R, "Progesterone to prevent spontaneous preterm birth", Semin Fetal Neonatal Med, 19, pp.15~26 (2014)
9. How HY, "Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety", Ther Clin Risk Manag, 5, pp.55~64 (2009)
10. Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella, "Progesterone and preterm birth prevention: translating clinical trials data into clinical practice", Am J Obstet Gynecol, 206, pp.376~386 (2012)
11. Committee on Practice Bulletins—Obstetrics, The American College of Obstetricians and Gynecologists, "Practice bulletin no. 130: prediction and prevention of preterm birth", Obstet Gynecol, 120, pp.964~973 (2012)
12. Meis PJ, "Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate", N Engl J Med, 348, pp.2379~2385 (2003)
13. Saghafi N, "Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery", J Obstet Gynaecol Res, 37, pp.1342~1345 (2011)
14. Winer N, "17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial", Am J Obstet Gynecol, 212, pp.485.e1-10~ (2015)
15. Senat MV, "Prevention of preterm delivery by 17alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial", Am J Obstet Gynecol, 208, pp.194.e1-8~ (2013)
16. Rozenberg P, "Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alphahydroxyprogesterone caproate: a randomized controlled trial", Am J Obstet Gynecol, 206, pp.206.e1-9~ (2012)
17. Facchinetti F, "Cervical length changes during preterm cervical ripening:effects of 17-alpha-hydroxyprogesterone caproate", Am J Obstet Gynecol, 196, pp.453.e1-4~ (2007)
18. Cicinelli E, "Mechanisms of uterine specificity of vaginal progesterone", Hum Reprod, 15(1), pp.159~165 (2000)
19. Levy T, "Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction", Steroids, 65, pp.645~649 (2000)
20. Hassan SS, "Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial", Ultrasound Obstet Gynecol, 38, pp.18~31 (2011)
21. Norman JE, "Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis", Lancet, 373, pp.2034~2040 (2009)
22. O’Brien JM, "Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial", Ultrasound Obstet Gynecol, 30, pp.687~696 (2007)
23. Wood S, "Vaginal progesterone to prevent preterm birth in multiple pregnancy: a randomized controlled trial", J Perinat Med, 40, pp.593~599 (2012)
24. Cetingoz E, "Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial", Arch Gynecol Obstet, 283, pp.423~429 (2011)
25. da Fonseca EB, "Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study", Am J Obstet Gynecol, 188, pp.419~424 (2003)
26. Majhi P, "Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomised trial in India", J Obstet Gynaecol, 29, pp.493~498 (2009)
27. Fonseca EB, "Progesterone and the risk of preterm birth among women with a short cervix", N Engl J Med, 357, pp.462~469 (2007)
28. Brizot ML, "Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study", Am J Obstet Gynecol, 213, pp.82.e1-9~ (2015)
29. El-Refaie W, "Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety", Arch Gynecol Obstet, 293, pp.61~67 (2016)
30. Rode L, "Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone", Ultrasound Obstet Gynecol, 38, pp.272~280 (2011)
31. Serra V, "Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial", BJOG, 120, pp.50~57 (2013)
32. Arikan I, "Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor", Gynecol Obstet Invest, 72, pp.269~273 (2011)
33. Borna S, "Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial", Aust N Z J Obstet Gynaecol, 48, pp.58~63 (2008)
34. Saleh Gargari S, "Outcome of vaginal progesterone as a tocolytic agent: randomized clinical trial", ISRN Obstet Gynecol, 2012, pp.607906~ (2012)
35. Martinez de Tejada B, "Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial", BJOG, 122, pp.80~91 (2015)
36. Palacio M, "Vaginal progesterone as maintenance treatment after an episode of preterm labour (PROMISE)study: a multicentre, double-blind, randomised, placebocontrolled trial", BJOG, 123, pp.1990~1999 (2016)
37. Iams JD, "Care for women with prior preterm birth", Am J Obstet Gynecol, 203, pp.89~100 (2010)
38. Edlow AG, "Second-trimester loss and subsequent pregnancy outcomes: what is the real risk?", Am J Obstet Gynecol, 197, pp.581.e1-6~ (2007)
39. McManemy J, "Recurrence risk for preterm delivery", Am J Obstet Gynecol, 196, pp.576.e1-6~ (2007)
40. Spong CY, "Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery", Am J Obstet Gynecol, 193, pp.1127~1131 (2005)
41. Azargoon A, "Vaginal progesterone on the prevention of preterm birth and neonatal complications in high risk women: a randomized placebo-controlled double-blind study", Int J Reprod Biomed (Yazd), 14, pp.309~316 (2016)
42. Norman JE, "Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial", Lancet, 387, pp.2106~2116 (2016)
43. DeFranco EA, "Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial", Ultrasound Obstet Gynecol, 30, pp.697~705 (2007)
44. Rai P, "Oral micronized progesterone for prevention of preterm birth", Int J Gynaecol Obstet, 104, pp.40~43 (2009)
45. Glover MM, "A randomized trial of micronized progesterone for the prevention of recurrent preterm birth", Am J Perinatol, 28, pp.377~381 (2011)
46. Grimes-Dennis J, "Cervical length and prediction of preterm delivery", Curr Opin Obstet Gynecol, 19, pp.191~195 (2007)
47. Iams JD, "The length of the cervix and the risk of spontaneous premature delivery", N Engl J Med, 334, pp.567~572 (1996)
48. Iams JD, "The preterm prediction study: recurrence risk of spontaneous preterm birth", Am J Obstet Gynecol, 178, pp.1035~1040 (1998)
49. Goldenberg RL, "The preterm prediction study: risk factors in twin gestations. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network", Am J Obstet Gynecol, 175, pp.1047~1053 (1996)
50. Guzman ER, "Use of cervical ultrasonography in prediction of spontaneous preterm birth in twin gestations", Am J Obstet Gynecol, 183, pp.1103~1107 (2000)
51. Romero R, "Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix:an updated meta-analysis including data from the OPPTIMUM study", Ultrasound Obstet Gynecol, 48, pp.308~317 (2016)
52. Society for Maternal Fetal Medicine Publications Committee, "ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth", Obstet Gynecol, 112, pp.963~965 (2008)
53. Pedretti MK, "Implementing universal cervical length screening in asymptomatic women with singleton pregnancies: challenges and opportunities", Aust N Z J Obstet Gynaecol, 57, pp.221~227 (2017)
54. Rozenberg P., "Universal cervical length screening for singleton pregnancies with no history of preterm delivery, or the inverse of the Pareto principle", BJOG, 124, pp.1038~1045 (2017)
55. Romero R, "Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data", Am J Obstet Gynecol, 206, pp.124.e1-19~ (2012)
56. Fuchs F, "Multiple gestations and preterm birth", Semin Fetal Neonatal Med, 21, pp.113~120 (2016)
57. Biggio JR, "Spontaneous preterm birth in multiples", Clin Obstet Gynecol, 58, pp.654~667 (2015)
58. Schuit E, "Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis", BJOG, 122, pp.27~37 (2015)
59. Rouse DJ, "A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins", N Engl J Med, 357, pp.454~461 (2007)
60. Briery CM, "Progesterone does not prevent preterm births in women with twins", South Med J, 102, pp.900~904 (2009)
61. Lim AC, "Effect of 17-alpha hydroxyprogesterone caproate on cervical length in twin pregnancies", Ultrasound Obstet Gynecol, 40, pp.426~430 (2012)
62. Awwad J, "A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN):evidence for reduced neonatal morbidity", BJOG, 122, pp.71~79 (2015)
63. Aboulghar MM, "The use of vaginal natural progesterone for prevention of preterm birth in IVF", ICSI pregnancies, 2012, pp.25, 133~138
64. Romero R, "Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data", Ultrasound Obstet Gynecol, 49, pp.303~314 (2017)
65. Hall NR, "What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?", Obstet Gynecol Clin North Am, 38, pp.235~246 (2011)
66. Elovitz MA, "Can medroxyprogesterone acetate alter Toll-like receptor expression in a mouse model of intrauterine inflammation?", Am J Obstet Gynecol, 193, pp.1149~1155 (2005)
67. Briery CM, "The use of 17-hydroxy progesterone in women with arrested preterm labor: a randomized clinical trial", J Matern Fetal Neonatal Med, 27, pp.1892~1896 (2014)
68. Lotfalizadeh M, "The effects of progesterone therapy on the gestation length and reduction of neonatal complications in patients who had received tocolytic therapy for acute phase of preterm labor", Iran Red Crescent Med J, 15, pp.e7947~ (2013)
69. Saccone G, "17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials", Am J Obstet Gynecol, 213, pp.16~22 (2015)
70. Briery CM, "Women with preterm premature rupture of the membranes do not benefit from weekly progesterone", Am J Obstet Gynecol, 204, pp.54.e1-5~ (2011)
71. Suhag A, "Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials", Am J Obstet Gynecol, 213, pp.479~487 (2015)
72. Choudhary M, "Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor", Int J Gynaecol Obstet, 126, pp.60~63 (2014)
73. Maher MA, "Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone", Acta Obstet Gynecol Scand, 92, pp.215~222 (2013)
74. Bafghi AS, "Comparative study of vaginal versus intramuscular progesterone in the prevention of preterm delivery: a randomized clinical trial", Electron Physician, 7, pp.1301~1309 (2015)
75. Pirjani R, "17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: a randomized controlled trial", J Obstet Gynaecol Res, 43, pp.57~64 (2017)
76. Elimian A, "A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth", Int J Gynaecol Obstet, 134, pp.169~172 (2016)
77. Saccone G, "Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials", Ultrasound Obstet Gynecol, 49, pp.315~321 (2017)
78. Golub MS, "“Natural” progesterone: information on fetal effects", Birth Defects Res B Dev Reprod Toxicol, 77, pp.455~470 (2006)
79. Brent RL, "Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation", Birth Defects Res A Clin Mol Teratol, 73, pp.906~918 (2005)
80. Raman-Wilms L, "Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis", Obstet Gynecol, 85, pp.141~149 (1995)
81. Northen AT, "Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo", Obstet Gynecol, 110, pp.865~872 (2007)
82. Armstrong J, "Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP", N Engl J Med, 364, pp.1689~1691 (2011)
83. Miles RA, "Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study", Fertil Steril, 62, pp.485~490 (1994)
84. Friedler S, "Luteal support with micronized progesterone following in-vitro fertilization using a downregulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration", Hum Reprod, 14, pp.11944~1948 (1999)
85. Ahn KH, "The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality", J Perinat Med, 45, pp.11~20 (2017)
86. Combs CA, "17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial", Am J Obstet Gynecol, 213, pp.364.e1-12~ (2015)

관련 논문AI추천